A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phaseNandini Sakurikar(Dartmouth College), Alan Eastman(Dartmouth College)OncotargetNovember 22, 201510.18632/oncotarget.6364Cited by 74SaveCiteExport RISWatch citationsRelated PapersSensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction|Scientific Reports|2021|14